Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations


Haznedaroglu I. C.

EXPERT OPINION ON PHARMACOTHERAPY, cilt.14, ss.2005-2010, 2013 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 14 Konu: 15
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1517/14656566.2013.833185
  • Dergi Adı: EXPERT OPINION ON PHARMACOTHERAPY
  • Sayfa Sayıları: ss.2005-2010

Özet

Introduction: The aim of this paper is to indicate optimal tyrosine kinase inhibitor (TKI) administration practices based on European LeukemiaNet (ELN) 2013 recommendations for chronic myeloid leukemia (CML). Likewise, current concerns of undertreatment and overtreatment with TKIs during the long-term clinical course of CML will be outlined.